Author pages are created from data sourced from our academic publisher partnerships and public sources.
Risk of serious asthma exacerbations associated with long-acting beta agonists among patients with asthma: a retrospective cohort study.
- J. Guo, K. Tsai, Christina M. L. Kelton, B. Bian, P. Wigle
- Annals of allergy, asthma & immunology : official…
- 1 March 2011
BACKGROUND After the Serevent Nationwide Surveillance clinical trial, controversy has surrounded the safety of long-acting beta agonists (LABAs). OBJECTIVE Examine the association between LABAs and… Expand
Comparison of potentially hepatotoxic drugs among major US drug compendia.
- J. Guo, P. Wigle, K. Lammers, Oceana Vu
- Research in social & administrative pharmacy…
- 1 September 2005
BACKGROUND Although a large number of drugs include warnings or listed adverse reactions that describe reports of associated hepatotoxicity, the hepatotoxic risk is documented with different… Expand
Updated guidelines on outpatient anticoagulation.
- P. Wigle, Bradley E. Hein, H. Bloomfield, M. Tubb, M. Doherty
- American family physician
- 15 April 2013
The American College of Chest Physicians provides recommendations for the use of anticoagulant medications for several indications that are important in the primary care setting. Warfarin, a vitamin… Expand
ACE Inhibitor and ARB utilization and expenditures in the Medicaid fee-for-service program from 1991 to 2008.
- B. Bian, Christina M. L. Kelton, J. Guo, P. Wigle
- Journal of managed care pharmacy : JMCP
- 1 November 2010
BACKGROUND Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are widely prescribed for the treatment of hypertension and heart failure, as well as for kidney… Expand
Safety of long-acting beta agonists and inhaled corticosteroids in children and adolescents with asthma
- Y. Xia, Christina M. L. Kelton, L. Xue, J. Guo, B. Bian, P. Wigle
- Therapeutic advances in drug safety
- 20 September 2013
The introduction of long-acting beta agonists (LABAs) was considered a major advance in bronchodilator therapy for adult, as well as pediatric, patients with asthma. However, the use of LABAs has… Expand
Utilization, Spending, and Price Trends for Quinolones in the US Medicaid Programs: 25 Years’ Experience 1991–2015
BackgroundGiven that the quinolones is one of the antibacterial classes most frequently used to treat patients with bacterial infections in the United States, any change in prescribing patterns of… Expand
Febuxostat: A Novel, Non-Purine Xanthine Oxidase Inhibitor
Objective: To review the pharmacology and clinical data for febuxostat in the treatment of gout and hyperuricemia. Data Sources: Articles on febuxostat published in English between 1966 and November… Expand
National Burden of Pediatric Hospitalizations for Inflammatory Bowel Disease: Results From the 2006 Kids’ Inpatient Database
- P. Heaton, Namita L. Tundia, N. Schmidt, P. Wigle, Christina M. L. Kelton
- Journal of pediatric gastroenterology and…
- 1 April 2012
Objectives: The objective of the present study was to quantify the national pediatric inpatient inflammatory bowel disease (IBD) burden in terms of the number of IBD-related hospitalizations, the… Expand
Evaluating safety of long-acting beta agonists (LABAs) in patients with asthma.
The introduction of long-acting beta agonists (LABAs) was considered a major advance in bronchodilator therapy with evidence that their use led to improved lung function and quality of life. However,… Expand
Current Practices in Global/International Advanced Pharmacy Practice Experiences: Preceptor and Student Considerations
- Emily K. Dornblaser, A. Ratka, +11 authors N. Z. Alsharif
- American Journal of Pharmaceutical Education
- 25 April 2016
The objective of this article is to describe the key areas of consideration for global/international advanced pharmacy practice experience (G/I APPE) preceptors, students and learning objectives. At… Expand